| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V10510 | CAY10444 | 298186-80-8 | CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist. |
|
V1502 | Fingolimod (FTY720) HCl | 162359-56-0 | Fingolimod HCl (formerly FTY-720; FTY 720; Gilenia and Gilenya), an FDA approved drug for the treatment of Multiple sclerosis, is a S1P (sphingosine 1-phosphate) antagonist with potential antineoplastic activity. |
|
V23005 | JTE-013 HCl | 383150-41-2 | JTE-013 HCl is a novelm potent, selective antagonist of sphingosine-1-phosphate 2 (S1P2) receptor, with IC50 of 17 and 22 nM, respectively, (IC50 >10 µM for for binding to human S1P1 and S1P3). |
|
V1506 | Opaganib (ABC294640) | 915385-81-8 | Opaganib (formerly known as ABC294640; ABC-294640; Trade name Yeliva) is a novel, potent, selective, competitive and orally bioavailable aryladamantane analog and selective sphingosine kinase-2 (SphK2) inhibitor with potential anticancer activity. |
|
V1507 | Ozanimod (RPC1063) | 1306760-87-1 | Ozanimod (formerly RPC-1063; trade name Zeposia) is a selective and orally bioavailable S1P Receptor 1 modulator that has been approved as an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. |
|
V4144 | PF-429242 | 947303-87-9 | PF429242 (PF-429242) is a novel, potent, reversible and competitive S1P [sterol regulatory element-binding protein (SREBP) site 1 protease] inhibitor with an IC50 of 170 nM. |
|
V1504 | PF-543 | 1415562-82-1 | PF-543 (also called PF543; PF 543; Sphingosine Kinase 1 Inhibitor II) is a novel cell-permeable and sphingosine-competitive inhibitor of SphK1 with potential antitumor activity. |
|
V15276 | Phorbol 12-myristate 13-acetate (PMA) | 16561-29-8 | Phorbol 12-myristate 13-acetate (PMA) is a novel and potent protein kinase C (PKC) agonist with the potential for the treatment of acute myeloid leukemia and cardiac fibrosis. |
|
V22749 | Ponesimod | 854107-55-4 | Ponesimod (formerly known as ACT-128800; ACT128800; Ponvory) is an orally bioavailable and selective agonist of sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) approved in 2021 by FDA to treat relapsing forms of multiple sclerosis. |
|
V1505 | Siponimod (BAF312) | 1230487-00-9 | Siponimod (BAF-312; WHO-9491; NVP-BAF-312; Mayzent) is anovel, potent and orally bioavailable S1P receptor modulator with immunomodulating activity. |
|
V17399 | Siponimod fumarate (BAF312) | 1234627-85-0 | Siponimod (BAF-312) hemifumarate is a potent, selective sphingosine-1-phosphate (S1P) receptor modulator. |
|
V1503 | SKI II | 312636-16-1 | SKI II (also known as SphK-I2; Sphingosine kinase inhibitor II; SK-III) is a potent, highly selective, non-lipid and non-ATP-competitive sphingosine kinase (SphK) inhibitor with potential anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
